Skip to main content
Clinical Trials/NCT06621667
NCT06621667
Not Yet Recruiting
N/A

Response of Lung Function, Chest Mobility, and Kyphotic Curve to Diaphragmatic Myofascial Release in Hyperkyphotic Subjects: A Randomized Controlled Trial

Cairo University0 sites42 target enrollmentOctober 10, 2024
ConditionsHyperkyphosis

Overview

Phase
N/A
Intervention
Not specified
Conditions
Hyperkyphosis
Sponsor
Cairo University
Enrollment
42
Primary Endpoint
maximum voluntary ventilation
Status
Not Yet Recruiting
Last Updated
last year

Overview

Brief Summary

kyphotic subjects have respiratory disturbances due to weakening of the diaphragm, responsible for inhalation, which lead to abnormalities in respiratory mechanics and abnormal gas exchange, leading to respiratory complications. Myofascial release of the diaphragm is an intervention intended to indirectly stretch the diaphragm muscle fibers to reduce muscle tension, normalize fiber length, and promote the efficiency of muscle contraction. Although diaphragm myofascial release has been used in clinical practice, to the best of the authors' knowledge, the current study is the first research investigating the effect of diaphragmatic myofascial release on lung function, chest mobility and kyphotic curve in hyperkyphotic subjects.

Registry
clinicaltrials.gov
Start Date
October 10, 2024
End Date
December 30, 2024
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Marwa Shafiek Mustafa Saleh

assistance professor doctor

Cairo University

Eligibility Criteria

Inclusion Criteria

  • The participant's age ranged from 20 to 40 years.
  • kyphosis angle 40-50◦
  • reporting pain on palpation of the diaphragm

Exclusion Criteria

  • A history of respiratory diseases, heart disease, vascular disease, central nervous system disorder, psychiatric disorders, hypertension.
  • History of any trauma or fracture to the thoracic spine.
  • inflammatory diseases such as rheumatoid arthritis, musculoskeletal problem and neurological deficit
  • Restrictive respiratory disease, smokers.

Outcomes

Primary Outcomes

maximum voluntary ventilation

Time Frame: change from base line at 4 weeks.

the maximum voluntary ventilation will be measured using spirometer

Secondary Outcomes

  • Chest expansion(change from base line at 4 weeks.)
  • kyphotic angle(change from base line at 4 weeks.)

Similar Trials